Please join us for a webinar with Dr. David Albala, on March 26, 12noon EST!

Title: Beyond PSA: The ExoDx Prostate™ test (EPI) as a Precision Genomic Biomarker

Description:

Prostate cancer is a leading cause of cancer for men within the United States with estimates in 2020 of more than 191,000 new cases per year, and 30,000 deaths. The current gold standard for prostate cancer diagnosis – needle biopsy – often lacks a true reflection of the molecular profile of the tissue given sampling error and complex tumor heterogeneity. Further, the relative lack of PSA specificity for prostate cancer has led to over-diagnosis of clinically insignificant prostate cancer.

There is growing demand for diagnostic tools that provide prognostic information to identify the right patient to undergo biopsy at the right time, while avoid missing high-grade prostate cancers (HGPCa). Liquid biopsy is a non-invasive method that may improve early detection of high grade prostate cancer and therefore inform patients’ treatment selection. The ExoDx™ Prostate Test, or “EPI” is a validated, non-invasive urine gene expression assay that provides actionable information that aids the prostate biopsy decision for men in the PSA ‘gray zone’ of 2-10ng/mL and is not dependent on clinical factors such as PSA, and other clinical risk factors.

Learning objectives:

• Address practical challenges in prostate cancer screening and diagnosis and clinical utility of
• analyzing exosomal RNA
• Review validation studies demonstrating performance of ExoDx Prostate urine gene assay in the
• “intended use” population
• Highlight clinical utility in real world urology group practices
• Evaluate performance of ExoDx prostate with standard of care parameters, such as PSA and risk
• calculators

About the speaker:

Dr. David M. Albala is Chief of Urology at Crouse Hospital in Syracuse, New York. He is considered a national and international authority in laparoscopic and robotic urological surgery and has been an active teacher in this area for over 20 years. His research and clinical interests have focused on robotic urological surgery. In addition, other clinical interests include minimally invasive treatment of benign prostatic hypertrophy (BPH) and the use of fibrin sealants in surgery. He has been a Visiting Professor at numerous institutions across the United States as well as overseas in countries such as India, China, Iceland, Germany, France, Japan, Brazil, Australia, and Singapore. In addition, he has done operative demonstrations in over 32 countries and 23 states. He has trained 16 fellows in endourology and advanced robotic surgery.

In addition, Dr. Albala is a past White House Fellow who acted as a special assistant to Federico Pena, Secretary of Transportation, on classified and unclassified public health related issues.